Browsing by Author "Moss, Alan"
Now showing items 1-15 of 15
-
Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD
Moss, Alan C; Lillis, Yvonne; Edwards George, Jessica B.; Choudhry, Niteesh Kumar; Berg, Anders Hayden; Cheifetz, Adam S.; Horowitz, Gary Leigh; Leffler, Daniel Alexander (Springer Nature, 2014)OBJECTIVES: Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and ... -
The Burden of Inflammatory Bowel Disease: A Patient-Reported Qualitative Analysis and Development of a Conceptual Model
Devlen, Jennifer; Beusterien, Kathleen; Yen, Linnette; Ahmed, Awais; Cheifetz, Adam S.; Moss, Alan C (Ovid Technologies (Wolters Kluwer Health), 2014)Background The aim of this study was to describe the impacts of inflammatory bowel disease (IBD) from the patients’ perspective, and to inform the development of a conceptual model. Methods Focus groups and ... -
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
Lawlor, GO; Moss, Alan (Dove Press, 2009-12-09)Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s disease over the last 10 years. Given the similarities between Crohn’s disease and ulcerative ... -
Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis
Sura, Siddharth P.; Ahmed, Awais; Cheifetz, Adam S.; Moss, Alan C (Ovid Technologies (Wolters Kluwer Health), 2014)Goals and Background Inflammatory bowel disease (IBD) serology testing is often used in patients with indeterminate colitis (IC) to help distinguish between ulcerative colitis (UC) and Crohn’s disease (CD). We investigated ... -
Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease
Longhi, Maria Serena; Moss, Alan; Bai, Aiping; Wu, Yan; Huang, Huang; Cheifetz, Adam; Quintana, Francisco J.; Robson, Simon C. (Public Library of Science, 2014)Induced regulatory T-cells (iT-reg) and T helper type 17 (Th17) in the mouse share common CD4 progenitor cells and exhibit overlapping phenotypic and functional features. Here, we show that human Th17 cells endowed with ... -
In Silico Promoter Analysis can Predict Genes of Functional Relevance in Cell Proliferation: Validation in a Colon Cancer Model
Moss, Alan; Doran, P; MacMathuna, P. (Sage, 2007-02)Specific combinations of transcription-factor binding sites in the promoter regions of genes regulate gene expression, and thus key functional processes in cells. Analysis of such promoter regions in specific functional ... -
Iron Replacement in Patients with Inflammatory Bowel Disease – A Systematic Review and Meta-Analysis
Abhyankar, Anita; Moss, Alan (Oxford University Press (OUP), 2015-08)Background A number of controlled trials and prospective studies have compared intravenous (IV) to oral (PO) iron for the treatment of IDA, with mixed results. Methods We conducted a systematic review of trials ... -
Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease
Abhyankar, A; Ham, M; Moss, Alan (Wiley, 2013-07-15)Background The rate of IBD exacerbation during pregnancy varies in the published literature. Aim We sought to perform a systematic review and meta-analysis of the effects of disease activity at conception on disease ... -
NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine
Bai, Aiping; Moss, Alan; Rothweiler, Sonja; Serena Longhi, Maria; Wu, Yan; Junger, Wolfgang G.; Robson, Simon C. (Nature Pub. Group, 2015)Interferon gamma (IFNγ)-producing CD8+ T cells (Tc1) play important roles in immunological disease. We now report that CD3/CD28-mediated stimulation of CD8+ T cells to generate Tc1 cells, not only increases IFNγ production ... -
Nephrolithiasis in patients with inflammatory bowel disease in the community
Cury, Dídia Bismara; Moss, Alan C; Schor, Nestor (Dove Medical Press, 2013)Background: Inflammatory bowel disease (IBD) has been associated with renal stone formation. The objective of this study was to determine prospectively the prevalence of nephrolithiasis in a community-based population of ... -
Novel treatment options for ulcerative colitis
Vaughn, Byron P; Moss, Alan C (OMICS Publishing Group, 2013)The approved treatment options for patients with ulcerative colitis (UC) are currently limited to mesalamine or immunosuppressants. Patients who do not respond to mesalamine-based therapy can be treated with immunomodulators ... -
Optimizing the use of biological therapy in patients with inflammatory bowel disease
Moss, Alan C. (Oxford University Press, 2015)Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved—or ... -
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis
Rostholder, E; Ahmed, A; Cheifetz, AS; Moss, Alan (Wiley, 2012-01-13)Background Infliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described. Aim To ... -
Prevention of post-operative recurrence of Crohn’s disease
Vaughn, Byron; Moss, Alan (Baishideng Publishing Group Inc., 2014)Endoscopic and clinical recurrence of Crohn’s disease (CD) is a common occurrence after surgical resection. Smokers, those with perforating disease, and those with myenteric plexitis are all at higher risk of recurrence. ... -
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
Nanda, Kavinderjit; Moss, Alan C. (Dove Medical Press, 2012)Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, ...